Les psychédéliques, traitements du futur | Lucie Berkovitch | TEDxAgroParisTech

Dr. Lucie Berkovitch, a psychiatrist and cognitive neuroscience researcher at Saint-Anne Hospital in Paris, delivers a comprehensive overview of psychedelics and their therapeutic potential. She begins by distinguishing psychedelics from popular cultural stereotypes, defining them as substances that trigger unique psychological experiences. The transcript covers four primary psychedelic substances: ayahuasca, LSD, psilocybin mushrooms, and mescaline, all of which can be synthesized in laboratories.

Berkovitch provides historical context, explaining that psychedelics were used ritually for millennia before arriving in the West in the late 19th century. A pivotal moment occurred in 1943 when Swiss chemist Albert Hoffman accidentally discovered LSD while working on ergot derivatives, likely through improper hand hygiene and subsequent eye contact. Initially, psychiatrists self-experimented with psychedelics to understand hallucinations experienced by schizophrenic patients. Early therapeutic studies showed mixed results, and the counterculture movement of the 1960s led to widespread use and subsequent government bans in 1970, halting legitimate research for two decades.

Research resumed in the 1990s with advances in brain imaging technology. Berkovitch then discusses ketamine, an anesthetic with rapid antidepressant effects discovered around 2000, which revolutionized acute psychiatric care but requires repeated administration and doesn't provide lasting effects. This contrasts with psychedelics, which demonstrate both immediate and sustained therapeutic benefits.

The speaker presents clinical evidence showing psychedelics' efficacy: studies from 2010 onward demonstrated that psilocybin and LSD reduced anxiety by 60% in palliative care patients; 30-50% of depression patients achieved remission lasting weeks to months; and 60-80% of tobacco users quit permanently after psychedelic-assisted therapy, with alcohol-dependent patients reducing consumption by five-fold. Psychedelics are always administered alongside psychotherapy, which serves dual purposes: ensuring safety and potentiating therapeutic benefits.

Berkovitch explains the neurological mechanisms through brain imaging studies. Psychedelics activate the 5HT2A serotonin receptor, causing desynchronization and apparent "anarchy" of brain activity. This results in increased sensory processing, enhanced positive emotion sensitivity while reducing negative emotion reactivity, decreased self-focused rumination, and altered predictive brain functions. Critically, neurons physically grow and form new connections during and after the experience, enabling lasting brain reconfiguration that psychotherapy can leverage.

The speaker addresses safety concerns directly, noting that scientific studies have documented no cases of severe decompensation, persistent psychosis, or addiction to psychedelics themselves. The benefit-risk ratio appears exceptionally favorable compared to conventional treatments. However, psychedelics remain unavailable in routine French medical care and are only accessible through experimental research protocols at specialized hospitals like Saint-Anne.

Berkovitch concludes by acknowledging the challenges of implementing psychedelics in underfunded public hospital systems that currently operate under severe resource constraints, emphasizing that research progress requires collective effort, political support, and concrete financial investment alongside rigorous scientific methodology.